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Hemolytic uremic syndrome (HUS) is characterized 
by the clinical triad of microangiopathic hemolytic 
anemia, thrombocytopenia, and acute kidney injury. 
Atypical Hemolytic Uremic Syndrome (aHUS) refers 
to non-Shiga-toxin HUS and is a primary thrombotic 
microangiopathic disease due to chronic, uncontrolled 
activation of the complement system. Complement-
mediated HUS is a relatively rare, life threatening 
disorder caused by mutations in the genes that 
encode complement proteins.
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A 68 year-old male with a past medical history of three previous hospitalizations 
for unexplained acute renal failure presented with fever, chills and a transient 
rash on his forearms. On admission his serum creatinine was 0.95mg/dl. He 
quickly developed anuric renal failure with a rapidly rising creatinine requiring 
initiation of hemodialysis. Peripheral smear demonstrated schistocytes. Labs 
revealed thrombocytopenia, anemia, and hypocomplementemia. A renal 
biopsy was performed which demonstrated features of membranoproliferative 
glomerulonephritis and thrombotic microangiopathy. Initial therapy included high 
dose steroids and the initiation of plasmapheresis, however he has since been 
started on Eclizumab.
The diagnosis of complement-mediated HUS remains 
challenging and is based on the clinical presentation of 
microangiopathic hemolytic anemia, thrombocytopenia, and 
acute kidney injury, not meeting criteria for typical HUS  and 
TTP.1  Mutations in proteins that regulate the alternative 
complement pathway such as Factor H (CFH), membrane 
cofactor protein (MCP or CD46), and Factor I (IF) have been 
implicated in causing aHUS.2 In the past, plasma exchange 
was first line treatment however Eculizumab, a humanized 
monoclonal antibody to C5, has now been shown to more 
effective resulting in decreased morbidity.3
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